Semaglutide and tirzepatide, a dual analogue of GLP-1and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist, have been added to the pharmaceutical arsenal against T2DM. Here, GIP is linked to type 2 diabetes mellitus.